Cagrisema
Also known as: Cagrilintide + Semaglutide, CagriSema Combination
A combination of cagrilintide and semaglutide for enhanced weight loss effects.
Overview
Cagrisema is a combination therapy pairing cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1 agonist). The dual mechanism targets both amylin and GLP-1 pathways for potentially superior weight loss compared to either agent alone. Currently in Phase 3 trials.
Mechanism of Action
Cagrilintide activates amylin receptors (appetite suppression, gastric emptying). Semaglutide activates GLP-1 receptors (appetite suppression, insulin secretion). The combination provides complementary and potentially synergistic effects on food intake and metabolism.
Pharmacokinetics
Both components are long-acting. Weekly subcutaneous injection. Designed for convenient combination dosing.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Clinical Trials
2.5/2.5 to 10/10 mg
Once weekly
68 weeks in trials
Dose escalation protocol
Research Areas
Key Research Findings
- 1Up to 20%+ weight loss in Phase 2 trials
- 2Potentially superior to semaglutide alone
- 3Dual mechanism of action
- 4Phase 3 trials ongoing
Side Effects & Contraindications
Reported Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
Contraindications
- MTC history
- MEN2
- Severe GI disease
- Pancreatitis history
Safety Considerations
Investigational combination. GI side effects similar to GLP-1 agonists. Expected to have similar contraindications to semaglutide.
Storage Requirements
Refrigerate 2-8°C
Scientific References
- 1